TXR-1007

TXR-1007 is an investigational **small molecule** drug candidate from Aria Pharmaceuticals being developed for **idiopathic pulmonary fibrosis**. Publicly available information indicates that it emerged from Aria's AI-enabled discovery platform and showed **preclinical efficacy and tolerability** in a bleomycin-induced mouse model of pulmonary fibrosis, with reported reductions in fibrosis and lung collagen staining versus standard-of-care comparator nintedanib. Aria has described TXR-1007 and its companion program TXR-1002 as having **distinct novel mechanisms of action**, but the specific molecular target and detailed mechanism for TXR-1007 have not been publicly disclosed in the sources reviewed. The program appears to remain at the **preclinical** stage.